Sullivan Maren, Rybicki Lisa A, Winter Aurelia, Hoffmann Michael M, Reiermann Stefanie, Linke Hannah, Arbeiter Klaus, Patzer Ludwig, Budde Klemens, Hoppe Bernd, Zeier Martin, Lhotta Karl, Bock Andreas, Wiech Thorsten, Gaspert Ariana, Fehr Thomas, Woznowski Magdalena, Berisha Gani, Malinoc Angelica, Goek Oemer-Necmi, Eng Charis, Neumann Hartmut P H
Department of Nephrology, Section of Preventive Medicine, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany.
Ann Hum Genet. 2011 Nov;75(6):639-47. doi: 10.1111/j.1469-1809.2011.00671.x. Epub 2011 Sep 12.
Hereditary atypical hemolytic uremic syndrome (aHUS), a dramatic disease frequently leading to dialysis, is associated with germline mutations of the CFH, CD46, or CFI genes. After identification of the mutation in an affected aHUS patient, single-site gene testing of relatives is the preventive care perspective. However, clinical data for family counselling are scarce. From the German-Speaking-Countries-aHUS-Registry, 33 index patients with mutations were approached for permission to offer relatives screening for their family-specific mutations and to obtain demographic and clinical data. Mutation screening was performed using direct sequencing. Age-adjusted penetrance of aHUS was calculated for each gene in index cases and in mutation-positive relatives. Sixty-one relatives comprising 41 parents and 20 other relatives were enrolled and mutations detected in 31/61. In total, 40 research participants had germline mutations in CFH, 19 in CD46 and in 6 CFI. Penetrance at age 40 was markedly reduced in mutation-positive relatives compared to index patients overall with 10% versus 67% (P < 0.001); 6% vs. 67% (P < 0.001) in CFH mutation carriers and 21% vs. 70% (P= 0.003) in CD46 mutation carriers. Age-adjusted penetrance for hereditary aHUS is important to understand the disease, and if replicated in the future, for genetic counselling.
遗传性非典型溶血性尿毒症综合征(aHUS)是一种常导致透析的严重疾病,与CFH、CD46或CFI基因的种系突变相关。在确诊一名患aHUS的患者的突变后,从预防保健角度出发,需对其亲属进行单基因检测。然而,用于家族咨询的临床数据却很匮乏。我们从德语国家aHUS注册中心联系了33名携带突变的索引患者,请求他们允许为其亲属进行家族特异性突变筛查,并获取人口统计学和临床数据。采用直接测序法进行突变筛查。计算索引病例和突变阳性亲属中每个基因的aHUS年龄调整后的外显率。共纳入61名亲属,包括41名父母和20名其他亲属,其中31/61检测到突变。总共40名研究参与者的CFH基因存在种系突变,19名的CD46基因存在突变,6名的CFI基因存在突变。与总体索引患者相比,突变阳性亲属在40岁时的外显率明显降低,分别为10% 对67%(P < 0.001);CFH突变携带者为6% 对67%(P < 0.001),CD46突变携带者为21% 对70%(P = 0.003)。遗传性aHUS的年龄调整后的外显率对于理解该疾病很重要,如果未来能得到重复验证,则对遗传咨询也很重要。